|Awarded On||February 21, 2019|
|Title||Development of a Precision Drug to Target STAG2 (SA2)–Mutant Ewing Sarcoma|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Debananda Pati|
|Cancer Sites||Bone, Brain and Other Nervous System, Leukemia|
*Pending contract negotiation
Currently, no good therapy exists for Ewing Sarcoma (EWS), a type of bone cancer in children and adolescents that has an aggressive disease phenotype and poor prognosis. EWS occurs most commonly in the second decade of life, with a rate of 0.3 cases per million in children younger than 3 years of age, and as high as 4.6 cases per million in adolescents aged 15–19 years. Long-term survival for metastatic EWS is <20%. A rare pediatric cancer, EWS has received little attention from researchers and less interest from pharmaceuticals to develop new drugs. Our goal is to develop a precision therapy against EWS that is safe and effective with minimal side effects, and which spares normal develop...